leadf
logo-loader
viewEli Lilly and Co

Eli Lilly says baricitinib cuts COVID-19 recovery time if used with Gilead Inc’s remdesivir

The rheumatoid arthritis treatment was shown to speed up recovery by one day

Eli Lilly and Co - Eli Lilly says baricitinib cuts COVID-19 recovery time if used with Gilead Inc’s remdesivir

Eli Lilly and Co (NYSE:LLY) said its baricitinib recovery time of COVID-19 patients if paired with Gilead Inc’s (NASDAQ:GILD) remdesivir.

The pharma company conducted a trial on over 1,000 patients, which started in May.

Baricitinib in combination with remdesivir reduced the recovery time by a day in comparison with remdesivir alone.

Remdesivir was developed to treat Ebola but trials recently have shown it to be effective in people with severe conditions resulting from coronavirus, cutting the time they spend in intensive care and reducing the virus’s ability to reproduce.

Based on results from this trial, Lilly plans to discuss the potential for emergency use authorisation with the US Food and Drug Administration and to explore similar measures with other regulatory agencies.

If authorised for use, Lilly will propose that baricitinib be available through commercial channels and will work with hospitals and governments to ensure patient access.

The drug is currently approved in more than 70 countries as a treatment for adults with moderately to severely active rheumatoid arthritis.

Quick facts: Eli Lilly and Co

Price: 147.44 USD

NYSE:LLY
Market: NYSE
Market Cap: $141.04 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

FansUnite Entertainment pleased Canada taking a look at allowing single...

FansUnite Entertainment (CSE: FANS- OTCQB: FUNFF) President Darius Eghdami joined Steve Darling from Proactive with news the company is hailing the Canadian government’s decision to introduce legislation that would legalize single-event sports betting in Canada. Eghdami talks about why that...

2 days, 6 hours ago

2 min read